28 November 2019 | News
Enabling highly automated screening solution for latent tuberculosis in all throughput segments
image credit- verywellhealth.com
QIAGEN and DiaSorin have announced the U.S. launch of an automated workflow for QuantiFERON-TB Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms.
The U.S. Food and Drug Administration (FDA) approved the LIAISON QuantiFERON-TB Plus Test, developed by QIAGEN and DiaSorin to offer streamlined laboratory automation for latent TB screening, supporting the conversion from tuberculin skin tests to modern blood-based QuantiFERON technology.
The highly automated workflow on LIAISON platforms provides QuantiFERON customers a powerful, highly flexible automation option for all throughput ranges.
Embedding QuantiFERON assays in the broad assay menu of DiaSorin’s LIAISON analyzers also gives current LIAISON customers an attractive new assay option with significant growth potential.
The workflow pairs QIAGEN’s standard QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT, containing the core QuantiFERON technology) with DiaSorin’s newly launched LIAISON QuantiFERON-TB Plus detection assay. More than 8,000 LIAISON systems have been placed worldwide, primarily in hospital laboratories.